Abstract:

BACKGROUND: Studies have suggested that mesenchymal stem cells may be immune protection sites consisting of the bone marrow micro-environment. As chronic myeloid leukemia hematopoietic microenvironment abnormalities and immune abnormalities exist, mesenchymal stem cells in chronic myelogenous leukemia presumably play an important role in the pathological process.
OBJECTIVE: To observe the immunological characteristics and the existence of immune dysfunction of bone marrow-derived cancer stem cells from chronic myeloid leukemia in comparison with normal mesenchymal stem cells.
METHODS: Bone marrow mesenchymal stem cells were separated from the normal subjects and patients with chronic myeloid leukemia to detect the effect on T cell cycle, activation, inhibition and proliferation.
RESULTS AND CONCLUSION: There were no differences between mesenchymal stem cell from chronic myeloid leukemia patients and normal volunteers in cell morphology and phenotype, but the ability of mesenchymal stem cells from chronic myelogenous leukemia patients was decreased in inhibiting T cell proliferation, T cell cycle and activation and increased in T cell apoptosis. All these indicate that mesenchymal stem cells from chronic myelogenous leukemia patients have obvious immune function defects, which are not a preferred choice for autologous mesenchymal stem cell transplantation. Allogeneic mesenchymal stem cell transplantation is the best method to be used in patients with myelodysplastic syndrome.